Skip to contentP
Protara Therapeutics, Inc.
P
TARAProtara Therapeutics, Inc. Q3 2016 · 10-Q
Revenue—
Net Income-$7.11M-$7.11MN/M vs Q3 2015 EPS Diluted-$0.43-$0.43N/M vs Q3 2015 Operating Income-$7,166,000N/M Operating Cash Flowderived-$6,646,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protara Therapeutics, Inc. · CIK 1359931 · Engraved from SEC EDGAR
Free Cash Flowderived-$6,703,000N/M ended Sep 30, 2016 · filed Nov 7, 2016 · 38 d after period end